Brie Carter - Author on Grafa
Tudo
Yatsen swings to annual non-GAAP profit as skincare pivot reaches 53% of sales
Yatsen Holding (NYSE:YSG) reported fourth-quarter and full-year 2025 results on Monday, marking a definitive turning point in its multi-year transition from a mass-market cosmetics player to a premium, skincare-led beauty group.
FDA grants priority review to Takeda's first-in-class blood disorder treatment
Takeda (NYSE:TAK) and Protagonist Therapeutics (NASDAQ:PTGX) secured a major regulatory milestone on Monday as the U.S. Food and Drug Administration (FDA) granted Priority Review to rusfertide, an investigational treatment for polycythemia vera (PV).










